Prognostic impact of systemic immune-inflammation index (SII) on infarct size and clinical outcomes in patients with ST-segment elevation myocardial infarction

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature Pub Date : 2025-09-13 DOI:10.1016/j.ijcha.2025.101798

Ya-li Zhu , Lai Wei , Xu Wang , Yong Zhou , Jun Pu

{"title":"Prognostic impact of systemic immune-inflammation index (SII) on infarct size and clinical outcomes in patients with ST-segment elevation myocardial infarction","authors":"Ya-li Zhu , Lai Wei , Xu Wang , Yong Zhou , Jun Pu","doi":"10.1016/j.ijcha.2025.101798","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Systemic immune-inflammation index (SII), calculated as platelet count × neutrophil count/lymphocyte count, is a novel and easily accessible inflammatory marker. Its prognostic value in predicting infarct size and major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) remains to be fully explored.</div></div><div><h3>Methods</h3><div>We analyzed 421 patients who underwent primary percutaneous coronary intervention (PCI) within 12 h of symptom onset, enrolled in a prospective multicenter registry (NCT03768453).All patients received immediate admission blood tests for SII calculation (platelet × neutrophil/lymphocyte counts) and completed standardized CMR imaging within 10 days post-PCI.Receiver operating characteristic (ROC) analysis identified the optimal SII cut-off value (914) to predict large infarct size (≥20 % of left ventricular mass). Patients were stratified into high (≥914) and low (<914) SII groups. The relationships between SII, infarct size, and MACE were analyzed using multivariate logistic and Cox regression models.</div></div><div><h3>Results</h3><div>Patients with high SII had significantly larger infarct size (median 29.0 % vs. 22.3 %, p < 0.001). SII ≥ 914 was independently associated with large infarct size (OR 1.889, 95 %CI: 1.100–3.242, p = 0.021) and higher incidence of MACE (HR 1.874, 95 % CI: 1.255–2.796, p = 0.002).</div></div><div><h3>Conclusions</h3><div>Elevated SII (≥914) independently associates with larger infarct size and increased MACE risk post-PCI, suggesting potential utility in risk stratification.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101798"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJC Heart and Vasculature","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352906725002015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Systemic immune-inflammation index (SII), calculated as platelet count × neutrophil count/lymphocyte count, is a novel and easily accessible inflammatory marker. Its prognostic value in predicting infarct size and major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) remains to be fully explored.

Methods

We analyzed 421 patients who underwent primary percutaneous coronary intervention (PCI) within 12 h of symptom onset, enrolled in a prospective multicenter registry (NCT03768453).All patients received immediate admission blood tests for SII calculation (platelet × neutrophil/lymphocyte counts) and completed standardized CMR imaging within 10 days post-PCI.Receiver operating characteristic (ROC) analysis identified the optimal SII cut-off value (914) to predict large infarct size (≥20 % of left ventricular mass). Patients were stratified into high (≥914) and low (<914) SII groups. The relationships between SII, infarct size, and MACE were analyzed using multivariate logistic and Cox regression models.

Results

Patients with high SII had significantly larger infarct size (median 29.0 % vs. 22.3 %, p < 0.001). SII ≥ 914 was independently associated with large infarct size (OR 1.889, 95 %CI: 1.100–3.242, p = 0.021) and higher incidence of MACE (HR 1.874, 95 % CI: 1.255–2.796, p = 0.002).

Conclusions

Elevated SII (≥914) independently associates with larger infarct size and increased MACE risk post-PCI, suggesting potential utility in risk stratification.

查看原文本刊更多论文

全身免疫炎症指数（SII）对st段抬高型心肌梗死患者梗死面积和临床结局的预后影响

系统免疫炎症指数（SII）是一种新的、容易获得的炎症标志物，由血小板计数×中性粒细胞计数/淋巴细胞计数计算而成。其预测st段抬高型心肌梗死（STEMI）患者经皮冠状动脉介入治疗（PCI）后梗死面积和主要不良心血管事件（MACE）的预后价值仍有待充分探讨。方法：我们分析了421例在症状出现12小时内接受了原发性经皮冠状动脉介入治疗（PCI）的患者，这些患者被纳入前瞻性多中心登记（NCT03768453）。所有患者在pci术后10天内立即接受血液检查进行SII计算（血小板×中性粒细胞/淋巴细胞计数），并完成标准化CMR成像。受试者工作特征（ROC）分析确定了预测大面积梗死（≥左心室质量的20%）的最佳SII临界值（914）。将患者分为高（≥914）和低（<914） SII组。采用多变量logistic和Cox回归模型分析SII、梗死面积和MACE之间的关系。结果SII高的患者梗死面积明显增大（中位数分别为29.0%和22.3%,p < 0.001）。SII≥914与较大的梗死面积（OR 1.889, 95% CI: 1.100-3.242, p = 0.021）和较高的MACE发生率（HR 1.874, 95% CI: 1.255-2.796, p = 0.002）独立相关。结论SII升高（≥914）与pci后梗死面积增大和MACE风险增加独立相关，提示在风险分层中有潜在的应用价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

IJC Heart and Vasculature Medicine-Cardiology and Cardiovascular Medicine

CiteScore

4.90

自引率

10.30%

发文量

216

审稿时长

56 days

期刊介绍： IJC Heart & Vasculature is an online-only, open-access journal dedicated to publishing original articles and reviews (also Editorials and Letters to the Editor) which report on structural and functional cardiovascular pathology, with an emphasis on imaging and disease pathophysiology. Articles must be authentic, educational, clinically relevant, and original in their content and scientific approach. IJC Heart & Vasculature requires the highest standards of scientific integrity in order to promote reliable, reproducible and verifiable research findings. All authors are advised to consult the Principles of Ethical Publishing in the International Journal of Cardiology before submitting a manuscript. Submission of a manuscript to this journal gives the publisher the right to publish that paper if it is accepted. Manuscripts may be edited to improve clarity and expression.